Novo Nordisk Expands Semaglutide Studies for Alcohol Use Disorder and Obesity | Eli Lilly's Foundayo Obesity Pill Receives FDA Approval | Wave Life Sciences Plunges After Obesity Data | Deep Learning Predicts Adult Obesity via Fitness Data | Mike Tyson Opens Up About Obesity Struggles and Super Bowl Ad | Oprah Winfrey on Weight Loss: Obesity as a Disease and Finding "Enough" | New Oral GLP-1 Agonist Shows Promise in Obesity Treatment | Wave Life Sciences' RNA Obesity Shot Shows Promising Results | Novo Nordisk Expands Semaglutide Studies for Alcohol Use Disorder and Obesity | Eli Lilly's Foundayo Obesity Pill Receives FDA Approval | Wave Life Sciences Plunges After Obesity Data | Deep Learning Predicts Adult Obesity via Fitness Data | Mike Tyson Opens Up About Obesity Struggles and Super Bowl Ad | Oprah Winfrey on Weight Loss: Obesity as a Disease and Finding "Enough" | New Oral GLP-1 Agonist Shows Promise in Obesity Treatment | Wave Life Sciences' RNA Obesity Shot Shows Promising Results
Novo Nordisk is broadening its research into semaglutide, originally developed for diabetes and obesity, to explore its potential in treating alcohol use disorder. Simultaneously, the company is advancing its pipeline with LX9851, an oral d...
Can GLP-1s quiet drug cravings? How a RI program is finding out
The Food and Drug Administration (FDA) has approved Foundayo, a new obesity pill manufactured by Eli Lilly, providing patients with another option for weight management. This once-daily pill aims to compete with the pill form of Wegovy and...
The FDA approves a new obesity pill, giving patients another option
Wave Life Sciences (WVE) stock plummeted after the release of interim data from an early-stage trial of its RNA-based obesity medicine, WVE-007. The trial data, focusing on healthy individuals, led to a sharp negative reaction from Wall Str...
Wave Life Sciences plunges after obesity data (WVE:NASDAQ)
Researchers have developed a deep learning model that predicts obesity in adults by analyzing physical fitness data. This model addresses the global challenge of obesity and its related health implications, from cardiovascular disease to re...
Deep Learning Predicts Adult Obesity via Fitness Data
Boxing legend Mike Tyson is sharing his personal journey with obesity and his decision to star in a Super Bowl ad focused on ultra-processed foods. He discusses his partnership with the MAHA Center and their mission to promote healthy eatin...
MAHA and Mike Tyson want you to ‘eat real food’ during the Super Bowl
Oprah Winfrey has openly discussed her decades-long battle with weight, and a recent epiphany has shifted her perspective. She now views obesity as a treatable disease, not a personal failing, which has influenced her approach to weight man...
"Enough": Oprah Winfrey on her weight-loss lessons
Structure Therapeutics has announced positive topline data from its ACCESS program for aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist. The studies show promising results in weight loss for individuals with obesity or...
Biotech Soars On Potential 'Best-In-Class' Obesity Drug
Wave Life Sciences (Nasdaq: WVE) has announced positive interim data from its Phase 1 INLIGHT trial of WVE-007 (INHBE), an investigational RNA medicine for treating obesity. The single-dose study demonstrated significant improvements in bod...
Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss
The landscape of obesity treatment is evolving rapidly with the emergence of new pill-based medications and innovative alternatives to traditional injectables. This article explores the latest advancements in obesity pills and alternative t...
5 things to know about the new obesity pills that are on the way
The Trump administration has announced landmark deals with Eli Lilly and Novo Nordisk to significantly reduce the prices of some obesity drugs, aiming to expand access to these costly treatments. The agreements will affect Medicare and Medi...
Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
Pfizer's $4.9 billion investment in Metsera is showing early promise. A Phase IIb trial of their obesity drug, MET-097i, has demonstrated a significant 14.1% weight loss in patients. This development positions Pfizer to be a strong contende...
Pfizer Just Reminded Investors Why You Should Never Count Its Stock Out
Pfizer (PFE) is strategically re-entering the competitive GLP-1 market, targeting the rapidly expanding obesity drug sector. With the acquisition of Metsera for $4.9 billion, Pfizer aims to secure a significant position in this lucrative ma...
Pfizer’s Bold GLP‑1 Comeback, Dividend Safe For Now (NYSE:PFE)
The once-promising obesity drug market faces a turning point as investor enthusiasm cools amidst concerns over lackluster results, potential copycat drugs, and pricing pressures. Pharmaceutical giants Novo Nordisk and Eli Lilly are now unde...
Obesity drug market hits turning point after lackluster results and lull in startups
This health news roundup for July 14, 2025, covers critical issues in health equity, including the disproportionate rise in obesity among minority youth, legal challenges to COVID-19 vaccine rollbacks, disparities in treatment access, and g...
Health Equity & Access Weekly Roundup: July 14, 2025
Eli Lilly (LLY) is witnessing robust demand for its diabetes and weight-loss drug, Mounjaro, in India, driven by increasing rates of obesity and diabetes. The company is focused on meeting this rising demand, positioning Mounjaro as a key p...
Eli Lilly (LLY) Sees Strong Demand for Mounjaro in India | LLY S
Queen Latifah is making headlines for her upcoming biopic, her performance at Coachella, and her continued advocacy for obesity awareness. Additionally, her influence on queer representation in film is being celebrated through the lens of t...
Queen Latifah reflects on multifaceted career, upcoming biopic, more
Novo Nordisk A/S (NVO), the Denmark-based global healthcare giant, is currently a focal point in the pharmaceutical sector. Fueled by the success of its popular diabetes and obesity treatments like Ozempic and Wegovy, the company's strong f...